hero-line-left hero-line-top
For Health Systems

Insights from a global oncology network

Syapse Oncology enables healthcare providers to deliver consistent, cost-effective, patient-centered cancer care.

hero-line-bottom
hero-line-horizontal
temp-hero-icon

The complexity of precision medicine requires insights from the real world


Syapse offerings for health systems enable:

icon circle checkmark High-level oversight of the practice of precision medicine at your health system
icon circle checkmark Optimization of your clinical trial portfolio for your real-world oncology patient population
icon circle checkmark The application of molecular diagnostics data to clinical care decisions
  • Syapse Executive

    Actionable insights to understand and improve the success of your precision medicine program.

  • Syapse Insights

    Use integrated clinical and molecular data to increase access to clinical trials and publish studies.

  • Syapse Oncology

    Use clinical and molecular data to support decision making and streamline workflows.

Connectivity with clinical databases, systems, and sources

Precision medicine requires centralized access to patient data that are typically siloed in electronic health records (EHRs), data warehouses, registries, and other systems. Syapse integrates patients’ clinical, pathology, radiology, treatment, lab results, and other information in a central data store to provide a single point of access.

Direct integration with molecular labs to capture structured molecular data

Today, genomic and other molecular test results are typically scanned into EHR systems and stored as unstructured data. Through direct integration with molecular diagnostics labs, Syapse enables healthcare systems to capture molecular profiles as structured data that can be used for decision support in the clinical workflow.

Common data standards across the network

Syapse standardizes and normalizes a robust set of data from multiple systems, allowing health systems to share data with other institutions, including patient demographics, cancer diagnoses, tumor genomics, tumor markers, treatments, and outcomes.

Resources

What's new

Syapse Announces Research Using Real-World Evidence at ASCO20 Virtual

SAN FRANCISCO – May 29, 2020 – Syapse today announced multiple research abstracts based on real-world data at the ASCO20 Virtual Annual Meet…

Read

Blog

Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses the findings from our collaborative research

Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer wh…

Read